Chitosan-Thiamine Pyrophosphate as a Novel Carrier for siRNA Delivery
- First Online:
- 340 Downloads
A novel siRNA carrier was formulated between chitosan (CS) and thiamine pyrophosphate (TPP). Their ability to deliver siRNA were evaluated in stable and constitutive EGFP-expressing HepG2 cells.
CS-TPP was prepared by dissolving CS in TPP solution at a CS:TPP molar ratio of 1.5:1. Complexes of CS-TPP/siRNA were formed at varying weight ratios and characterized using gel electrophoresis. Their morphologies and particle sizes were evaluated, and the transfection efficiency and cytotoxicity of CS-TPP/siRNA complexes were examined in stable and constitutive EGFP-expressing HepG2 cells.
Gel electrophoresis results indicated that binding of CS-TPP and siRNA depended on the molecular weight (MW) and weight ratio of CS, and the particle sizes of CS-TPP/siRNA complexes were in nano-size. The CS-TPP-mediated siRNA silencing of the endogenous EGFP gene occurred maximally with 70–73% efficiency. The CS-TPP/siRNA complex with the lowest MW of CS (20 kDa) at a weight ratio of 80 showed the strongest inhibition of gene expression, which was higher than Lipofectamine 2000™. Over 90% the average cell viabilities of the complexes were observed by MTT assay.
This study suggests that CS-TPP is straightforward to prepare, safe and exhibits significantly improved siRNA delivery potential in vitro.
KEY WORDSchitosan salts EGFP siRNA delivery thiamine pyrophosphate
- 3.R. C. Ryther, A. S. Flynt, J. A. Phillips, and J. G. Patton. siRNA therapeutics big potential from small RNAs. Gene Ther. 1:25–11 (2005).Google Scholar
- 5.F. Takeshita, Y. Minakuchi, S. Nagahara, K. Honma, H. Sasaki, K. Hirai, T. Teratani, N. Namatame, Y. Yamamoto, K. Hanai, T. Kato, A. Sano, and T. Ochiya. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:12177–12182 (2005) doi:10.1073/pnas.0501753102.PubMedCrossRefGoogle Scholar
- 6.C. N. Landen Jr., A. Chavez-Reyes, C. Bucana, R. Schmandt, M. T. Deavers, L.opez-G. Berestein, and A.K. Sood. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65:6910–6918 (2005) doi:10.1158/0008-5472.CAN-05-0530.PubMedCrossRefGoogle Scholar
- 13.F. C. MacLaughlin, R.J. Mumper, J. Wang, J.M. Tagliaferri, I. Gill, M. HinCHyiffe, and A.P. Rolland. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J. Control. Release. 56:259–272 (1998) doi:10.1016/S0168-3659(98)00097-2.PubMedCrossRefGoogle Scholar
- 18.X. Liu, K. A. Howard, M. Dong, M. O. Andersen, U. L. Rahbek, M. G. Johnsen, O. C. Hansen, F. Besenbacher, and J. Kjems. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials. 28:1280–1288 (2007) doi:10.1016/j.biomaterials.2006.11.004.PubMedCrossRefGoogle Scholar
- 19.J. Y. Pille, H. Li, E. Blot, J. R. Bertrand, L. L. Pritchard, P. Opolon, A. Maksimenko, H. Lu, J. P. Vannier, J. Soria, C. Malvy, and C. Soria. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 17:1019–1026 (2006) doi:10.1089/hum.2006.17.1019.PubMedCrossRefGoogle Scholar
- 21.K. A. Howard, U. L. Rahbek, X. Liu, C. K. Damgaard, S. Z. Glud, M. O. Andersen, M. B. Hovgaard, A. Schmitz, J. R. Nyengaard, F. Besenbacher, and J. Kjems. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14:476–484 (2006) doi:10.1016/j.ymthe.2006.04.010.PubMedCrossRefGoogle Scholar
- 23.P. C. Engel. Enzyme cofactors. In P. C. Engel (ed.), Enzymology LabFax, Academic, California, 1996, pp. 244–245.Google Scholar